Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $68.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on HALO. Piper Sandler boosted their price target on Halozyme Therapeutics […]
More Stories
AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price decreased by equities research analysts at JPMorgan Chase & Co....
Stock Traders Purchase Large Volume of Put Options on iShares U.S. Real Estate ETF (NYSEARCA:IYR)
iShares U.S. Real Estate ETF (NYSEARCA:IYR – Get Free Report) was the target of unusually large options trading activity on...
Profound Medical (NASDAQ:PROF) & Assure (NASDAQ:IONM) Head-To-Head Analysis
Profound Medical (NASDAQ:PROF – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but...
COVID-19 Vaccine Makers and Providers Granted Immunity Through 2029
By Sherami Tsai The Biden administration has extended liability protections for COVID-19 vaccine makers, health care providers, and others through...
Georgia Appeals Court Disqualifies Fani Willis From Trump Election Case
By Jack Phillips A Georgia appeals court has disqualified Fulton County District Attorney Fani Willis from her election-related criminal case...
Toll Brothers (NYSE:TOL) Shares Gap Down – What’s Next?
Toll Brothers, Inc. (NYSE:TOL – Get Free Report)’s stock price gapped down before the market opened on Thursday . The...